European Medicines Agency Validates Gilead’s Marketing Application for Investigational Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C
Foster City, Calif., December 4, 2015 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its Marketing Authorization Application (MAA) for…